SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amid mixed sentiment, with some community members highlighting its infrastructure role and potential for developers, while others express frustration with its price performance and call it a "scam token." Discussions also revolve around the upcoming Neura L1 blockchain and its potential impact on the token's utility and value, with some hoping for a coin burn mechanism to drive demand.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial guidance updates and the completed acquisition of Melinta Therapeutics, with the community actively discussing the potential impacts of the acquisition and future revenue projections. Some are concerned about potential executive stock sales, while others are optimistic about the company's growth and the potential for a short squeeze. Discussions also revolve around DefenCath's adoption rates and potential CMS policy changes.

Trump For President

TRUMP.X is trending as the crypto market reacts to speculation around Trump's political activities and potential influence on the coin's value. The community is actively discussing price predictions and potential pumps, while also debating the merits and risks associated with investing in meme coins linked to public figures. Broader market factors, including economic data and potential policy changes, are also being considered in relation to the token's future performance.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors discuss its aggressive capital allocation strategy amid strong gold prices, including a massive buyback program and significant shareholder returns. Community members are weighing the impact of these factors, alongside potential cost-cutting measures and unusual options activity, on the company's future performance and stock price, with some highlighting its potential for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Boston Scientific (BSX) This Year?

Here is how Boston Scientific (BSX) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Allarity Therapeutics, Inc. (ALLR) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Stenoparib. Following the announcement, shares of the company more than doubled in value by Tuesday afternoon.Stenoparib is an investigational treatment for patients with advanced ovarian cancer. FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval and priority review, upon meeting relevant criteria.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALLR">ALLR stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_16_43_PM_png_5d0f99e451.webp" alt="ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at the rally and opined that the stock might drop to below $1 by the end of the day.<stembedurl>https://stocktwits.com/patb99/message/626594104</stembedurl>Another user stated that larger pharmaceutical companies will now be interested in the drug.<stembedurl>https://stocktwits.com/Creyedr/message/626587898</stembedurl>Allarity CEO Thomas Jensen <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html">said</a> the company is pleased with the designation. “We look forward to engaging closely with the FDA as we advance this program,” he added.US-headquartered Allarity started patient enrollment under a new mid-stage clinical trial protocol evaluating Stenoparib in advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer in early June 2025. Several patients have already been dosed in the study. The trial is designed to accelerate clinical development of Stenoparib. Previous mid-stage study data showed durable clinical benefit for Stenoparib.The therapy was originally developed by Eisai Co., but Allarity secured exclusive global rights for the development and commercialization.ALLR stock has gained 74% this year but has lost 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Allarity Therapeutics Stock Double In Value Today?

The company’s Stenoparib, an investigational treatment for patients with advanced ovarian cancer, was granted the Fast Track designation by the FDA.

Equity

ReShape Lifesciences Inc. (1,900% Jump in Message Volume)ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse merger with Vyome Therapeutics, first announced in June 2024.&nbsp;The metabolic health solutions company stated in January that it was still working with the SEC on its S-4 filing and would set a shareholder meeting date once the filing is declared effective.Some investor interest also stemmed from reports that Michael Bigger’s fund had taken a significant stake in ReShape. However, sentiment remained mixed after the company raised $6 million through a public offering last month.&nbsp;ReShape’s stock is down nearly 80% year-to-date (YTD).Allarity Therapeutics Inc. (1,700% Jump in Message Volume)Allarity drew attention after announcing a Phase 2 trial evaluating the combination of stenoparib, a PARP inhibitor, with the chemotherapy agent temozolomide for treating recurrent small-cell lung cancer (SCLS). Prior studies had shown about a 40% response rate in SCLC patients, but dose-limiting toxicity remained a challenge.Additionally, Allarity’s Board of Directors authorized a $5 million share repurchase program on Monday, allowing buybacks through February 2026.&nbsp;The stock is down over 9% YTD.Exact Sciences Corporation (1,100% Jump in Message Volume)Exact Sciences, known for its cancer diagnostics, saw increased interest as it participated in the TD Cowen 45th Annual Healthcare Conference and Raymond James &amp; Associates’ 46th Annual Institutional Investors Conference last week.&nbsp;The company reiterated its plans to launch three new cancer screening tests in 2025, including Cologuard Plus (a next-generation colorectal cancer screening test), Oncodetect (a molecular residual disease test) and Cancerguard (a multi-cancer screening test).The company noted rising demand for rescreens, which grew 30% last year and are expected to grow another 30% this year.&nbsp;Exact Sciences’ stock is down over 18% YTD.CVS Health Corporation (700% Jump in Message Volume)CVS Health made headlines last week after announcing that Wellvana had acquired its Medicare Shared Savings Program business in an all-stock deal, giving CVS a strategic minority stake in Wellvana.On Saturday, The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/cvs-small-store-openings-b0e196a2">reported</a> that CVS plans to open a dozen new stores focused on full-service pharmacies with minimal retail space, a shift in response to declining retail sales across drugstore chains.&nbsp;The stock has gained 47% YTD.AbbVie Inc. (500% Jump in Message Volume)AbbVie’s stock gained traction after BofA raised its price target to $223 from $200, maintaining a ‘Neutral’ rating. The bullish revision followed AbbVie’s $350 million upfront deal with Gubra to develop GUB014295, a long-acting amylin analog targeting obesity.Under the agreement, Gubra could receive up to $1.88 billion in milestone payments, plus tiered royalties on global net sales.&nbsp;AbbVie shares are up nearly 20% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a  Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR) for...

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR) and reminds investors of...

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR SHAREHOLDER ALERT...

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Allarity...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on...

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

ALLR
Allarity Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ALLR News

ALLR Allarity Therapeutics Inc